Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Base Carbon Reports Second-Quarter 2025 Operating and Financial Results

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, togeth...

What is the market's perception of the company's long‑term positioning in the evolving carbon credit ecosystem? Did the company disclose any share repurchase plans, dividend policy, or other capital return initiatives? Is there any information on the company's exposure to regulatory or policy changes that could influence its business model?
Symbol: BCBN
Earnings
28 days ago
Read more globenewswire

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announce...

Will the crypto holdings be used for any strategic purposes (e.g., funding collaborations, M&A, or liquidity needs) or remain purely as a reserve asset? How might macro‑crypto market dynamics (e.g., Bitcoin price swings, network upgrades, or market sentiment) impact LIXTE's overall financial performance? What safeguards, custody solutions, and insurance policies does LIXTE have in place to protect against theft or loss of digital assets?
Symbol: LIXT
Corporate
28 days ago
Read more globenewswire

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA ...

What guidance does management provide on earnings per share (EPS) and dividend policy after the acquisition? How will this acquisition influence XOMA’s long‑term strategic positioning in the royalty‑based biotech investment space? Are there any regulatory or antitrust considerations that could delay or alter the transaction?
Symbol: XOMA
M&a
28 days ago
Read more globenewswire

Amerigo’s MVC Resumes Fresh Tailings Processing

VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) provides an operational update on Minera Valle Central ...

Are there any regulatory or environmental considerations tied to the fresh tailings processing that could affect future operations? Will the resumed processing affect the company's exposure to commodity price volatility or hedging strategies? How might this development influence analyst sentiment and target price revisions for Amerigo (ARG/ARREF)?
Symbol: ARG
Operations
28 days ago
Read more globenewswire

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China

How does this clinical success impact the overall risk profile of Sagimet's pipeline and its long‑term growth prospects? What is the projected market size for moderate to severe acne in China and globally, and how much market share can Sagimet realistically capture? Are there any contingent milestones or royalty structures tied to the Ascletis partnership that could impact future earnings?
Symbol: SGMT
Earnings
28 days ago
Read more globenewswire

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ℱ for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stag...

Are there any risks or contingencies disclosed that could delay or derail the clinical development of Bria‑OTS+? How might this news influence analyst coverage, target price revisions, or consensus estimates for BriaCell? Will the inclusion in the Accelerator program trigger any dilution from new equity issuances or convertible securities?
Symbol: BCTX
Clinical trials
28 days ago
Read more globenewswire

DeFi Technologies Announces Shareholder Call to Discuss Q2 2025 Financial Results

TORONTO, Aug. 13, 2025 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (the "Company" or "DeFi Technologies") (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial tech...

Are there any implications for the technical outlook of DEFT (trend direction, support/resistance levels) based on the earnings news? What does the call reveal about the company's balance sheet strength, liquidity position, and ability to fund future initiatives? How will the reported results affect the company's valuation multiples (e.g., P/E, P/S) and overall market perception?
Symbol: DEFT
Earnings
28 days ago
Read more prnewswire

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovat...

Are there any contingent or convertible securities (e.g., warrants, options) that could further dilute existing shareholders after the IPO? What are the key regulatory milestones for Nasus Pharma’s pipeline and how might they influence the stock’s risk profile? Who are the lead underwriters and what is their track record with similar pharmaceutical offerings?
Symbol: NSRX
Ipo
28 days ago
Read more globenewswire

Denison Announces Pricing of Upsized US$300 Million Convertible Senior Notes Offering

TORONTO, Aug. 13, 2025 /PRNewswire/ - Denison Mines Corp. (TSX: DML)(NYSE AMERICAN: DNN) ("Denison" or the "Company") announces that, on August 12, 2025, it upsized and priced its previously announ...

What are the potential tax implications of the convertible notes for the company and shareholders? How does this financing compare to Denison’s previous debt or equity raises in terms of cost and flexibility? What is the market’s reaction to the pricing (spread, demand) and what does it imply about investor sentiment?
Symbol: DNN
Finance
28 days ago
Read more prnewswire